338992-20-4

Basic information

• Product Name: Tert-butyl 4-((4-(4-bromo-2-fluorophenylamino)-6-methoxyquinazolin-7-yloxy)methyl)piperidine-1-carboxylate
• Synonyms: Tert-butyl 4-((4-(4-bromo-2-fluorophenylamino)-6-methoxyquinazolin-7-yloxy)methyl)piperidine-1-carboxylate;4-[[[4-[(4-Bromo-2-fluorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]-1-piperidinecarboxylic acid tert-butyl ester;1-Piperidinecarboxylic acid, 4-[[[4-[(4-broMo-2-fluorophenyl)aMino]-6-Methoxy-7-quinazolinyl]oxy]Methyl]-, 1,1-diMethylethyl ester;tert-Butyl 4-(((4-((4-bromo-2-fluorophenyl)amino)-6-methoxyquinazolin-7-yl)oxy)methyl)piperidine-;tert-Butyl 4-(((4-((4-bromo-2-fluorophenyl)amino)-6-methoxyquinazolin-7-yl)oxy)methyl)piperidi
• CAS NO: 338992-20-4
• Molecular Formula: C₂₆H₃₀BrFN₄O₄
• Molecular Weight: 561
• Mol File: 338992-20-4.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 608.714 °C at 760 mmHg
• Flash Point: 321.939 °C
• Appearance: /
• Density: 1.385
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.575
• Storage Temp.: 2-8°C(protect from light)
• CAS DataBase Reference: Tert-butyl 4-((4-(4-bromo-2-fluorophenylamino)-6-methoxyquinazolin-7-yloxy)methyl)piperidine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Tert-butyl 4-((4-(4-bromo-2-fluorophenylamino)-6-methoxyquinazolin-7-yloxy)methyl)piperidine-1-carboxylate(338992-20-4)
• EPA Substance Registry System: Tert-butyl 4-((4-(4-bromo-2-fluorophenylamino)-6-methoxyquinazolin-7-yloxy)methyl)piperidine-1-carboxylate(338992-20-4)

Safety Data

• Hazardous Substances Data: 338992-20-4(Hazardous Substances Data)

Usage

General Description

Tert-butyl 4-((4-(4-bromo-2-fluorophenylamino)-6-methoxyquinazolin-7-yloxy)methyl)piperidine-1-carboxylate is a chemical compound containing a piperidine ring and a quinazolinone moiety. It is a derivative of the drug quinazoline, which is known for its potential pharmaceutical applications. Tert-butyl 4-((4-(4-bromo-2-fluorophenylamino)-6-methoxyquinazolin-7-yloxy)methyl)piperidine-1-carboxylate has been synthesized for potential use in medicinal chemistry and drug development. The presence of the piperidine-1-carboxylate group suggests that it may have biological activity, as carboxylates are often involved in biochemical processes. The bromo, fluoro, and methoxy substituents on the phenylamino-quinazolin-7-yloxy group may confer specific properties or biological activities to the compound. Further research and testing would be needed to determine the specific pharmacological and biochemical properties of this chemical.

InChI:InChI=1/C7H7ClN2O/c8-5-1-2-10-6(3-5)4-7(9)11/h1-3H,4H2,(H2,9,11)

Upstream product

• 385785-02-4 2-amino-4-(benzyloxy)-5-methoxybenzonitrile 
• 385784-84-9 4-(benzyloxy)-5-methoxy-2-nitrobenzonitrile 
• 52805-34-2 4-(benzyloxy)-3-methoxybenzonitrile 
• 4421-08-3 3-methoxy-4-hydroxybenzonitrile 
• 123855-51-6 tert-butyl 4-(hydroxymethyl)piperidin-1-carboxylate 
• 723283-25-8 (E)-tert-butyl 4-((4-cyano-5-(((dimethylamino)methylene)amino)-2-methoxyphenoxy)methyl)piperidine-1-carboxylate 
• 367-24-8 4-bromo-2-fluoroaniline 
• 2426-87-1 3-methoxy-4-(phenylmethoxy)benzaldehyde 
• 193001-44-4 7-benzyloxy-4-chloro-6-methoxyquinazoline hydrochloride 
• 179688-01-8 7-(benzyloxy)-6-methoxyquinazolin-4(3H)-one 
• 60547-98-0 2-amino-4-benzyloxy-5-methoxybenzamide 
• 196603-96-0 4-(4-bromo-2-fluorophenylamino)-7-hydroxy-6-methoxyquinazoline 
• 60547-94-6 5-Methoxy-2-nitro-4-(phenylmethoxy)benzamide 
• 2426-84-8 4-(benzyloxy)-5-methoxy-2-nitrobenzaldehyde 

Downstream Products

• 910298-60-1 4-((4-bromo-2-fluorophenyl)amino)-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-6-ol 
• 1363151-84-1 N-(4-bromo-2-fluorophenyl)-6-methoxy-7-(piperidinyl-4-methoxy)quinazolin-4-amine hydrochloride 
• 1363151-86-3 (S)-(4-((4-bromo-2-fluorophenylamino)-6-methoxyquinazolinyl-7-oxy)methyl)-1-(piperidinyl-2-pyrrolidinyl)methanone hydrochloride 
• 1363153-84-7 C₃₇H₄₈BrFN₆O₆ 
• 1363153-79-0 (S)-N-((S)-1-((S)-2-(4-((4-bromo-2-fluorophenylamino)-6-methoxyquinazolinyl-7-oxy)methyl)piperidine)-1-carbonyl)-1-((pyrrolidinyl)-3,3-dimethyloxobutan-2-yl)-2-(methylamino)propanamide hydrochloride 
• 1363150-67-7 C₄₁H₅₅BrFN₇O₇ 
• 1363153-82-5 C₃₁H₃₇BrFN₅O₅ 
• 443913-73-3 vandetanib 
• 338992-12-4 N-Desmethylvandetanib 

Relevant articles and documents

Tyrosine kinase inhibitors implant he loni and its key intermediate for the preparation of

The invention discloses tyrosine kinase inhibitor implant he loni and its key intermediate of the preparation method, which belongs to the medicine, in the field of fine chemicals. The invention of the preparation method of gefitinib, is a brand-new preparation scheme, from whatever a intermediate starting, can be obtained in accordance with the requirements of the target compound. The method of the invention has short steps, the reaction operation is simple, safe and reliable, high yield, low cost, high purity, pollution little and simple operation and the like.

QUINOLINE OR QUINAZOLINE DERIVATIVES WITH APOPTOSIS INDUCING ACTIVITY ON CELLS

Provided is a pharmaceutical composition comprising, as an active ingredient, a quinoline or quinazoline derivative of formula (I), a pharmaceutically acceptable salt, an isomer, a hydrate, and a solvate thereof, which is effective in the prevention and treatment of a cancer, inflammation, autoimmune diseases or neurodegenerative disorders which are induced by the overexpression of inhibitor of apoptosis proteins (IAPs).

SUBSTITUTED QUINAZOLINE INHIBITORS OF GROWTH FACTOR RECEPTOR TYROSINE KINASES

The present invention relates to new substituted quinazoline inhibitors of vascular endothelial growth factor receptor tyrosine kinase, epidermal growth factor receptor tyrosine kinase, and/or REarranged during Transfection tyrosine kinase, pharmaceutical compositions thereof, and methods of use thereof.